Breaking News

These “Breaking news” sessions feature presentations on recent clinical trials, new developments in experimental science, and updates on other hot topics.

Mon 24 Apr 13:00
Late breaking news - PCSK9 inhibition, the clinical benefit

Chair:
  • Chris J. Packard
  • Alberico L. Catapano

LDL is causal to atherosclerosis

M. John Chapman, Paris, France

The EAS Consensus

FOURIER: first outcomes data with a PCSK9 inhibitor

Terje Pedersen, Oslo, Norway

In depth analysis of the data

Atherosclerosis regression: linking GLAGOV and FOURIER

Stephen Nicholls, Adelaide, Australia

Further analyses from Glagov

What do FOURIER data mean for clinical practice?

M. John Chapman, Paris, France

Stephen Nicholls, Adelaide, Australia

Terje Pedersen, Oslo, Norway

CV outcomes trials: where does FOURIER sit?

  • Relationship between LDL-C and CVD risk
  • Effects of PCSK9 inhibitors on LDL-C (PROFICIO and ODYSSEY programmes
  • Results of previous CVOT and comparison to FOURIER

Tue 25 Apr 11:00
Late breaking news - recent clinical trials and hot topics

siRNA to PCSK9 in patients with high Cardiovascular Risk and Elevated LDL-C: the ORION 1 Trial

Kausik Ray, London, United Kingdom

SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDY

Daniel Gaudet, Montreal, Canada

CARAT: WILL INFUSING A PRE-BETA HIGH-DENSITY LIPOPROTEIN MIMETIC (CER-001) REGRESS CORONARY ATHEROSCLEROSIS?

Stephen Nicholls, Adelaide, Australia

MILANO-PILOT: WILL INFUSING HDL MIMETICS CONTAINING APOA-IMILANO CONTINUE TO REGRESS CORONARY ATHEROSCLEROSIS IN THE MODERN ERA OF INTENSIVE STATIN THERAPY?

Stephen Nicholls, Adelaide, Australia

The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Daniel Gaudet, Montreal, Canada

Tue 25 Apr 14:00
Late breaking news - in experimental science

INSTABILITY OF LDL PARTICLES PREDICTS FUTURE CARDIOVASCULAR DEATHS

C1Q/TNF-RELATED PROTEIN 1 PROMOTES VASODILATORY DYSFUNCTIONS BY INCREASING ARGINASE 1 ACTIVITY AND UNCOUPLING OF ENDOTHELIAL NITRIC OXIDE SYNTHASE

MARGINAL ZONE B CELLS CONTROL FOLLICULAR HELPER T CELL RESPONSE TO HIGH CHOLESTEROL DIET

MONOCYTIC GLUTAREDOXIN 1 PROTECTS MICE AGAINST OBESITY, HYPERGLYCEMIA AND ATHEROSCLEROSIS